Skip to content

Stapled side-to-side anastomosis versus sutured end-to-end anastomosis following resection for primary or recurrent Crohn's disease

Multicentre randomised controlled trial to compare stapled side-to-side anastomosis with sutured end-to-end anastomosis following resection for primary or recurrent Crohn's disease

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN72500766
Enrollment
200
Registered
2005-09-09
Start date
2002-01-01
Completion date
Unknown
Last updated
2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Crohn?s disease Digestive System Crohn's disease [regional enteritis]

Interventions

Group 1: Hand sewn anastomosis Group 2: Stapled anastomosis

Sponsors

Mount Sinai Hospital (Toronto) (Canada)
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Women and men aged greater than 16 years 2. Elective ileocolonic resection 3. Colonoscopy and Small Bowel Endoscopy (SBE) completed with the last 3 years 4. Crohn?s Disease involving the terminal ileum plus or minus right colonic disease 5. No other sites of involvement with Crohn?s disease in the Gastrointestinal (GI) tract current or past 6. Willing to return for colonoscopy at 12 months

Exclusion criteria

Exclusion criteria: 1. Require emergency surgery 2. Have sites of Crohn?s involvement elsewhere, except for minimal perianal disease 3. Have had strictureplasties or other resections for Crohn?s disease performed either at this operation or previously, the exception being resections for fistula disease in bowel not affected by Crohn?s disease 4. Require a bypass procedure or defunctioning ileostomy during the index procedure 5. Have compromised renal function (serum creatinine level greater than 130 mmol/l or 1.5 mg/l) 6. Prednisone, budesonide, 5-Aminosalicylic Acid (5-ASA) medications, ciprofloxacin, metronidazole, cyclosporin and Anti-Tumour Necrotising Factor (Anti-TNF) and any other medications used to treat Crohn?s cannot be discontinued postoperatively 7. Are unable or willing to give informed consent and return for a colonoscopy at 12 months

Design outcomes

Primary

MeasureTime frame
Severe endoscopic recurrence at one year follow-up.

Secondary

MeasureTime frame
1. Symptomatic recurrence (up to 24 months after) 2. Post-operative complication rates 3. Operative times

Countries

Canada

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026